FDA Drugs (New Approvals & NDA)Original article
Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments - 06/23/2026
RegulatoryNeutral
AI Analysis
Summary
The FDA announced a public meeting and comment period on June 23, 2026 regarding financial transparency and efficiency of prescription drug, biosimilar, and generic drug user fee amendments.
Importance:2/10
Sentiment:
0.00
FDAPDUFAUser Fee ActBiosimilarGeneric DrugPublic CommentRegulatory
Read the original article
Published by FDA Drugs (New Approvals & NDA) on July 1, 2026 1:18 PM